ABIVAX SA (AAVXF:OTCMKTS)
$0 None (None%)
Analysed ABIVAX SA (AAVXF:OTCMKTS) News Sources
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer
04-08-2026
yahoo.com
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
07-09-2026
yahoo.com
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's Why
08-09-2026
yahoo.com
4 Biotech Stocks to Watch as Potential Takeover Targets
18-09-2026
yahoo.com
Abivax Presents Business Updates and First Half 2026 Financial Results
21-09-2026
yahoo.com
ABIVAX (ABVX) Uses More Cash. Can its Funding Cover a Potential Launch?
26-09-2026
yahoo.com
ABIVAX Société Anonyme (ENXTPA:ABVX) Appoints New Chief Medical And Technical Officers
26-09-2026
yahoo.com
ABIVAX Société Anonyme (ENXTPA:ABVX) Just Gave Investors Something To Think About
27-09-2026
yahoo.com
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
30-09-2026
yahoo.com
Abivax (ABVX): Cleared Safety Overhang and Phase 3 Data De-Risk Path to Commercialization
07-10-2026
yahoo.com
What is the current price of ABIVAX SA (AAVXF:OTCMKTS)?
The current price of ABIVAX SA (AAVXF:OTCMKTS) is $0.
ABIVAX SA (AAVXF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of ABIVAX SA (AAVXF:OTCMKTS) since the previous trading day is $None.
ABIVAX SA (AAVXF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of ABIVAX SA (AAVXF:OTCMKTS) since the previous trading day is None%.
What is the most recent average sentiment score for ABIVAX SA (AAVXF:OTCMKTS)?
The most recent average sentiment score for ABIVAX SA (AAVXF:OTCMKTS) is 79 out of 100.
What is the most recent average sentiment for ABIVAX SA (AAVXF:OTCMKTS)?
The most recent sentiment for ABIVAX SA (AAVXF:OTCMKTS) is .
SEC-8K** Filing Available For ABIVAX SA (AAVXF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.